Regulation of apoptosis through CD95 (APO-I/Fas) receptor-ligand interaction.
Debatin
K M
KM
University Children's Hospital, Heidelberg, Germany.
Beltinger
C
C
Böhler
T
T
Fellenberg
J
J
Friesen
C
C
Fulda
S
S
Herr
I
I
Los
M
M
Scheuerpflug
C
C
Sieverts
H
H
Stahnke
K
K
D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis / Q000276:immunology*; D053222:Fas Ligand Protein; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000502:physiology; D006801:Humans; D015458:Leukemia, T-Cell / Q000276:immunology / Q000473:pathology; D008232:Lymphoproliferative Disorders / Q000235:genetics / Q000276:immunology; D008562:Membrane Glycoproteins / Q000502:physiology*; D018448:Models, Immunological; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor / Q000502:physiology; D019014:fas Receptor / Q000235:genetics / Q000502:physiology*
D000970:Antineoplastic Agents; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D018124:Receptors, Tumor Necrosis Factor; D019014:fas Receptor